171 related articles for article (PubMed ID: 23438878)
1. Whole-genome sequencing in pharmacogenetics.
Urban TJ
Pharmacogenomics; 2013 Mar; 14(4):345-8. PubMed ID: 23438878
[No Abstract] [Full Text] [Related]
2. Ask the experts: pharmacogenomics and genome-wide association studies.
Hakonarson H
Pharmacogenomics; 2013 Mar; 14(4):365-8. PubMed ID: 23438883
[No Abstract] [Full Text] [Related]
3. Personalized pharmacogenomics profiling using whole-genome sequencing.
Mizzi C; Peters B; Mitropoulou C; Mitropoulos K; Katsila T; Agarwal MR; van Schaik RH; Drmanac R; Borg J; Patrinos GP
Pharmacogenomics; 2014 Jun; 15(9):1223-34. PubMed ID: 25141897
[TBL] [Abstract][Full Text] [Related]
4. Interview: a discussion on genome-wide associations in pharmacogenomics.
Motsinger-Reif A
Pharmacogenomics; 2013 Mar; 14(4):361-3. PubMed ID: 23438882
[No Abstract] [Full Text] [Related]
5. HLA: a pharmacogenomics success story.
Becquemont L
Pharmacogenomics; 2010 Mar; 11(3):277-81. PubMed ID: 20235781
[No Abstract] [Full Text] [Related]
6. Pharmacogenomics: historical perspective and current status.
Charlab R; Zhang L
Methods Mol Biol; 2013; 1015():3-22. PubMed ID: 23824846
[TBL] [Abstract][Full Text] [Related]
7. High-throughput framework for genetic analyses of adverse drug reactions using electronic health records.
Zheng NS; Stone CA; Jiang L; Shaffer CM; Kerchberger VE; Chung CP; Feng Q; Cox NJ; Stein CM; Roden DM; Denny JC; Phillips EJ; Wei WQ
PLoS Genet; 2021 Jun; 17(6):e1009593. PubMed ID: 34061827
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine.
Giacomini KM; Yee SW; Mushiroda T; Weinshilboum RM; Ratain MJ; Kubo M
Nat Rev Drug Discov; 2017 Jan; 16(1):1. PubMed ID: 27885282
[No Abstract] [Full Text] [Related]
9. Pharmacogenetics of second-generation antipsychotics.
Brennan MD
Pharmacogenomics; 2014 Apr; 15(6):869-84. PubMed ID: 24897292
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomics of adverse drug reactions: practical applications and perspectives.
Becquemont L
Pharmacogenomics; 2009 Jun; 10(6):961-9. PubMed ID: 19530963
[TBL] [Abstract][Full Text] [Related]
11. Using genome-wide association studies to identify genes important in serious adverse drug reactions.
Daly AK
Annu Rev Pharmacol Toxicol; 2012; 52():21-35. PubMed ID: 21819236
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics--10 years of progress: a cardiovascular perspective.
Winkelmann BR; Herrington D
Pharmacogenomics; 2010 May; 11(5):613-6. PubMed ID: 20415546
[TBL] [Abstract][Full Text] [Related]
13. Personalized pharmacogenomics: predicting efficacy and adverse drug reactions.
Pirmohamed M
Annu Rev Genomics Hum Genet; 2014; 15():349-70. PubMed ID: 24898040
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomic genome-wide association studies: lessons learned thus far.
Crowley JJ; Sullivan PF; McLeod HL
Pharmacogenomics; 2009 Feb; 10(2):161-3. PubMed ID: 19207016
[No Abstract] [Full Text] [Related]
15. Genomic technology applied to pharmacological traits.
Yang JJ; Plenge RM
JAMA; 2011 Aug; 306(6):652-3. PubMed ID: 21828330
[No Abstract] [Full Text] [Related]
16. Opportunities and challenges for genome sequencing in the clinic.
Cavalleri GL; Delanty N
Adv Protein Chem Struct Biol; 2012; 89():65-83. PubMed ID: 23046882
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide studies in pharmacogenomics: harnessing the power of extreme phenotypes.
Gurwitz D; McLeod HL
Pharmacogenomics; 2013 Mar; 14(4):337-9. PubMed ID: 23438876
[No Abstract] [Full Text] [Related]
18. Use of linkage analysis, genome-wide association studies, and next-generation sequencing in the identification of disease-causing mutations.
Londin E; Yadav P; Surrey S; Kricka LJ; Fortina P
Methods Mol Biol; 2013; 1015():127-46. PubMed ID: 23824853
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of drugs withdrawn from the market.
Zhang W; Roederer MW; Chen WQ; Fan L; Zhou HH
Pharmacogenomics; 2012 Jan; 13(2):223-31. PubMed ID: 22256871
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics of severe cutaneous adverse reactions.
Kaniwa N; Saito Y
Pharmacogenomics; 2013 Apr; 14(6):595-8. PubMed ID: 23570461
[No Abstract] [Full Text] [Related]
[Next] [New Search]
